<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00040833</url>
  </required_header>
  <id_info>
    <org_study_id>02-008</org_study_id>
    <secondary_id>CDR0000069411</secondary_id>
    <secondary_id>NCI-G02-2082</secondary_id>
    <nct_id>NCT00040833</nct_id>
  </id_info>
  <brief_title>Acupuncture and Acupressure in Treating Patients With Moderate or Severe Pain Related to Stage III or Stage IV Pancreatic Cancer</brief_title>
  <official_title>Acupuncture for the Treatment of Pancreatic Cancer Pain: A Single Arm Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Acupuncture and acupressure may help relieve moderate or severe pain associated&#xD;
      with stage III or stage IV pancreatic cancer.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of acupuncture and accupressure in&#xD;
      treating patients who have moderate or severe pain associated with stage III or stage IV&#xD;
      pancreatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Assess the effects of acupuncture and acupressure on pain, sedation, and use of opiate&#xD;
           medication in patients with moderate or severe pain related to stage III or IV&#xD;
           pancreatic cancer.&#xD;
&#xD;
        -  Determine whether controlled trials of this therapy are warranted in this patient&#xD;
           population.&#xD;
&#xD;
        -  Provide data to aid design of further warranted studies of this therapy in this patient&#xD;
           population.&#xD;
&#xD;
      OUTLINE: Patients receive acupuncture treatment comprising 20 minutes of needle insertion&#xD;
      into the arms and abdomen to the depth used in traditional Chinese medicine on approximately&#xD;
      days 4, 7, 11, and 14. After each acupuncture treatment, the acupuncturist applies/reapplies&#xD;
      acupressure devices by inserting 2-6 smaller needles (studs) into the abdomen (which are held&#xD;
      in place with surgical tape) and taping tiny metal balls to 3 points in each ear. Patients or&#xD;
      caregivers are instructed to administer acupressure by pressing on the ear points (metal&#xD;
      balls) for 1-2 minutes per point and moving the semi-permanent abdominal needles in small&#xD;
      circular movements with the fingers, at a rate of 2-3 cycles per second, for 1-2 minutes per&#xD;
      point, upon waking in the morning and in the early afternoon. Patients or caregivers are also&#xD;
      instructed to stimulate a &quot;rescue point&quot; (the Shenmen auricular point) if patients experience&#xD;
      pain exacerbations at other times during the day. Patients who respond well to acupuncture&#xD;
      are offered further treatment.&#xD;
&#xD;
      Pain is assessed using the numerical rating scale on approximately days 1-4, 7, 11, and&#xD;
      14-17. Sedation is assessed using the Profile of Mood States (POMS) on approximately days 3&#xD;
      and 17. Analgesic medication use is assessed on approximately days 1-3 and 15-17.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 10-29 patients will be accrued for this study within&#xD;
      approximately 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2002</start_date>
  <completion_date type="Actual">June 2003</completion_date>
  <primary_completion_date type="Actual">June 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Supportive Care</primary_purpose>
  </study_design_info>
  <condition>Pain</condition>
  <condition>Pancreatic Cancer</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>complementary or alternative medicine procedure</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>pain therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of stage III or IV primary pancreatic cancer&#xD;
&#xD;
          -  At least 4 days since prior change in type of pain medication&#xD;
&#xD;
          -  No change in dose of long-acting analgesics&#xD;
&#xD;
          -  Actual dose of as needed (PRN) pain medication may vary&#xD;
&#xD;
          -  One of the following pain scores:&#xD;
&#xD;
               -  Pain score of at least 4 on a scale of 0 to 10&#xD;
&#xD;
               -  A score of at least 54 out of 88 on the combined relevant Profile of Mood States&#xD;
                  (POMS) subscales (Vigor, Fatigue, and Confusion) with no evidence that sedation&#xD;
                  results from cause other than opiate medication and patient reported using PRN&#xD;
                  opiates on at least 4 of the past 7 days (patients who are eligible for this&#xD;
                  study on the basis of POMS scores must be taking PRN medication)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 4 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 500/mm^3&#xD;
&#xD;
          -  Platelet count at least 20,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  INR no greater than 2.5&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No heart valve dysfunction&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior gemcitabine unless there is documented disease&#xD;
             progression&#xD;
&#xD;
          -  Concurrent chemotherapy (except gemcitabine) allowed&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  At least 1 week since prior epidural analgesia, celiac plexus block, or thoracoscopic&#xD;
             or open splanchnicectomy&#xD;
&#xD;
          -  No concurrent epidural analgesia, celiac plexus block, or thoracoscopic or open&#xD;
             splanchnicectomy&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 months since prior acupuncture&#xD;
&#xD;
          -  Concurrent experimental treatments allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barrie R. Cassileth, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>July 8, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 4, 2013</last_update_submitted>
  <last_update_submitted_qc>June 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 5, 2013</last_update_posted>
  <keyword>stage III pancreatic cancer</keyword>
  <keyword>recurrent pancreatic cancer</keyword>
  <keyword>pain</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

